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Hypoxic respiratory failure is one of the most common-
est disorders leading to intensive care unit (ICU) admis-
sion and also a common reason for the deterioration of
patients already treated in the ICU. It is a very serious con-
dition associated with significant mortality [1, 2]. In re-
cent decades, research and scientific attention has focused
nearly exclusively on the pathophysiology and treatment
of established causes of hypoxic respiratory failure such
as cardiogenic pulmonary edema and the acute respiratory
distress syndrome (ARDS) [1, 2]. Therefore, our diagnos-
tic approach to patients with hypoxic respiratory failure
has remained both largely unchanged and poorly validated.
This is a dilemma because diagnostic uncertainty is very
common. The severity of disease and the requirement for
immediate ventilatory support often limit our ability to ob-
tain a detailed patient history and physical examination.
Chest X-ray is helpful but also associated with important
limitations [3].
Lefebvre and colleagues are to be congratulated for
shedding light on the diagnostic uncertainty associated
with hypoxic respiratory failure in the ICU. In this paper
they evaluate a novel approach to diagnose the cause of
hypoxic respiratory failure: the measurement of B-type
natriuretic peptides, specifically NT-proBNP [4]. B-type
natriuretic peptides are quantitative markers of cardiac
stress and heart failure (HF) summarizing the extent of
systolic and diastolic left ventricular dysfunction, valvular
dysfunction, and right ventricular dysfunction [5–7].
B-type natriuretic peptides have been shown to be ex-
tremely helpful in the diagnosis and prognosis of HF,
particularly in the emergency department (ED). As the
diagnostic dilemmas in the ICU are often as challenging
as in the ED, recent studies have begun to evaluate
whether the use of B-type natriuretic peptides might also
be helpful in the ICU [8–12]. Major differences in patient
characteristics, disease severity, comorbidity, resources
available for the individual patient, and therapies applied
between the ICU and the ED require that the potential
clinical use of B-type natriuretic peptides in the ICU be
defined by specific ICU studies.
Lefebvre and colleagues examined the use of NT-
proBNP in 74 cancer patients presenting to the ICU with
hypoxic respiratory failure. The rationale for focusing
on cancer patients was based on the idea that rapid
identification of a cardiac cause of hypoxic respiratory
failure could avoid invasive procedures such as bron-
choscopy and bronchoalveolar lavage in these patients.
They found that NT-proBNP levels were significantly
higher in patients with cardiac causes (n = 16) than in
those with non-cardiac causes (n = 56). However, overall
the accuracy of NT-proBNP in diagnosing HF was only
moderate. NT-proBNP seemed helpful to rule out HF, but
not to reliably diagnose HF [4]. The diagnostic uncertainty
associated with respiratory failure in the ICU is high-
lighted by the fact that apparently 24 out of 74 patients
received a “furosemide trial”. Only 6 of these finally re-
ceived a gold standard diagnosis of HF. Therefore, furo-
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semide was inappropriately given to 18 patients, and
appropriately to only 6 patients. On the other hand, only 6
out of 16 patients with HF received furosemide.
The following considerations might help to put these
findings into perspective: First, this cohort of cancer
patients differs in many aspects from unselected patients
presenting with hypoxic respiratory failure [9, 10]. The
patients were roughly 20 years younger and had a very
low prevalence of HF as the cause of respiratory failure.
Therefore, the findings of this study most likely cannot
be transferred to a broader patient population. Second,
the ability of an observational study to reliably quantify
the diagnostic accuracy of a novel test depends on the
accuracy of the gold standard diagnosis. Thus, if the gold
standard is incorrect in 25% of patients, a hypothetically
perfect novel test with a true accuracy of 100% would
result in an accuracy of only 75%. The diagnostic uncer-
tainty associated with hypoxic respiratory failure in the
ICU is exemplified by several controversies regarding the
gold standard diagnosis used in this study. The diagnosis
of cardiac respiratory failure required “the absence of
infection or non-infectious pulmonary involvement”. This
is misleading, as infection is a well-established trigger of
acute HF [13]. Also, this definition neglects the clinical
reality of two disorders being present and significantly
contributing to respiratory failure at the same time. In
addition, the gold standard diagnosis in this paper heavily
relies on echocardiography. Unfortunately, the echocar-
diographic diagnosis of left ventricle diastolic dysfunction
in critically ill patients is often challenging [14, 15]. We
lack systematic studies that have validated, for example,
what constitutes normal diastolic function in a 75-year-old
woman with non-cardiac respiratory failure receiving
positive-pressure ventilation. This limitation is further
aggravated by the fact that echocardiography and NT-
proBNP testing were performed at different times during
ICU stay, as left ventricle diastolic function may change
rapidly in response to therapy. Unfortunately, another
limitation comes on top of this. As acknowledged by
the authors, the detection of a cardiac dysfunction does
not imply that the diagnosis of HF is the main cause of
respiratory failure. For instance, a patient may have had
myocardial infarction 10 years ago: his left ventricular
ejection fraction is 40%, which classifies him as having
systolic left ventricular dysfunction. If this patient devel-
ops respiratory failure due to pneumonia, his echo will be
altered at admission but the cause of his respiratory failure
is extra-cardiac.
The inherent dilemma of lack of accepted and vali-
dated gold standard diagnosis in observational studies can
ultimately only be overcome by performing randomized
controlled trials that apply objective measures of patient
outcome as endpoints. The primary results of a large
randomized controlled multicenter study (BASEL II–ICU)
will soon become available and help to further elucidate
the approach to ICU patients with hypoxic respiratory
failure. BASEL II–ICU tests the hypothesis that the use
of B-type natriuretic peptide levels in ICU patients with
respiratory failure might help to more rapidly and more
accurately detect the cause of respiratory failure and
ultimately improve patient management and reduce total
treatment cost.
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